Omega-3 fatty acids and mild cognitive impairment in older adults
Effects of omega-3 fatty acids high in eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA) vs placebo on cognition and mood in older adults with mild cognitive impairment
Nutritional Physiology Research Centre
120 participants
Feb 18, 2009
Interventional
Conditions
Summary
This study aims to investigate effects of omega-3 fatty acids EPA vs DHA (1500mg per day of each, supplying total omega-3 fatty acids 1860mg and 1680mg per day, respectively) versus safflower oil placebo on cognition and mood in 120 older adults with mild cognitive impairment over 6 months at two sites, in South Australia and Queensland. We will be measuring erythrocyte fatty acid levels, cerebral blood flow and blood vessel reactivity via transcranial Doppler sonography (tcD) and carbogen (5% carbon dioxide, 95% oxgen) inhalation, telomere length as an indicator of chromosomal damage, apoE-4, homocysteine, B12 and folate (the latter in collaboration with the Oxford Project to Investigate Memory and Ageing (OPTIMA) Centre for dementia research and the Commonwealth Scientific and Industrial Research Organisation (CSIRO) Human Nutrition). At baseline we will be doing comparisons on these outcome measures with a group of 30 healthy controls in South Australia. We are also assessing relationships between social networks, physical activity and above biomarkers, and cognitive impairment.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Six capsules containing omega-3 fatty acids plus Vitamin E, supplying a total of 360mg EPA + 1500mg DHA or 1500mg EPA + 180mg DHA per day for six months (26 weeks)
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12609000167268